- Home
- SNDX vs KOS Comparison
SNDX vs KOS Comparison
Compare SNDX & KOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNDX
- KOS
- Stock Information
- Founded
- SNDX 2005
- KOS 2003
- Country
- SNDX United States
- KOS United States
- Employees
- SNDX N/A
- KOS N/A
- Industry
- SNDX Biotechnology: Pharmaceutical Preparations
- KOS Oil & Gas Production
- Sector
- SNDX Health Care
- KOS Energy
- Exchange
- SNDX Nasdaq
- KOS Nasdaq
- Market Cap
- SNDX 1.1B
- KOS 817.4M
- IPO Year
- SNDX 2016
- KOS 2011
- Fundamental
- Price
- SNDX $9.00
- KOS $1.93
- Analyst Decision
- SNDX Strong Buy
- KOS Buy
- Analyst Count
- SNDX 10
- KOS 6
- Target Price
- SNDX $35.80
- KOS $4.52
- AVG Volume (30 Days)
- SNDX 1.8M
- KOS 13.0M
- Earning Date
- SNDX 07-31-2025
- KOS 08-04-2025
- Dividend Yield
- SNDX N/A
- KOS N/A
- EPS Growth
- SNDX N/A
- KOS N/A
- EPS
- SNDX N/A
- KOS N/A
- Revenue
- SNDX $43,722,000.00
- KOS $1,546,854,000.00
- Revenue This Year
- SNDX $426.77
- KOS N/A
- Revenue Next Year
- SNDX $98.31
- KOS $12.42
- P/E Ratio
- SNDX N/A
- KOS N/A
- Revenue Growth
- SNDX N/A
- KOS N/A
- 52 Week Low
- SNDX $8.58
- KOS $1.39
- 52 Week High
- SNDX $25.07
- KOS $5.97
- Technical
- Relative Strength Index (RSI)
- SNDX 38.70
- KOS 52.93
- Support Level
- SNDX $8.77
- KOS $1.70
- Resistance Level
- SNDX $9.50
- KOS $2.32
- Average True Range (ATR)
- SNDX 0.53
- KOS 0.13
- MACD
- SNDX -0.04
- KOS -0.02
- Stochastic Oscillator
- SNDX 14.13
- KOS 45.16
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
About KOS Kosmos Energy Ltd. (DE)
Kosmos Energy Ltd is a deepwater exploration and production company focused on meeting the world's growing demand for energy. It has diversified oil and gas production from assets offshore Ghana, Equatorial Guinea, Mauritania, Senegal and the Gulf of America. The Company had operations in four geographic reporting segments: Ghana, Equatorial Guinea, Mauritania/Senegal and the Gulf of America. The majority of revenue is derived from the Ghana segment.